First HER2-directed medicine to show an improvement in overall survival for previously treated metastatic gastric cancer with a 41% reduction in the risk of death vs. chemotherapy

Breakthrough Therapy Designation recently granted in the US for Enhertu in this setting

Attachments

  • Original document
  • Permalink

Disclaimer

AstraZeneca plc published this content on 29 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 May 2020 12:05:03 UTC